Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Post-Transplant Work Status of Young Adult Survivors of Allogeneic Hematopoietic Cell Transplant: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Neel S. Bhatt, Ruta Brazauskas, PhD, Stephanie Bo-Subait, MPH, Rachel B. Salit, MD, Karen Syrjala, PhD, Heather R. Tecca, Minoo Battiwalla, MD, David K. Buchbinder, MD MSHS, Betty K. Hamilton, MD, Rachel Phelan, MDMPH, Bronwen E. Shaw, MD PhD

Blood (2019) 134 (Supplement_1): 706.

https://doi.org/10.1182/blood-2019-124151

Published: 2019

Journal Articles

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes

Laura Roberts, Rachel B. Salit, MD, Lauren Longo, Elisabetta Xue, MD, Corinne Summers, MD, Colleen Delaney, MD MSc, Ann Dahlberg, MD, Filippo Milano, MD PhD

Blood (2019) 134 (Supplement_1): 2048.

https://doi.org/10.1182/blood-2019-126216

Published: 2019

Journal Articles

High Incidence of Herpes Zoster after Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis

Elisabetta Xue, MD, Hu Xie, Wendy Leisenring, ScD, Louise E Kimball, PhD RN, Sonia Goyal, Lisa Chung, Rachel Blazevic, Byron Maltez, Ann Dahlberg, MD, Rachel B. Salit, MD, Colleen Delaney, MD MSc, Steven A. Pergam, MDMPH, Michael Boeckh, MD, Filippo Milano, MD PhD, Joshua Aiden Hill, MD

Blood (2019) 134 (Supplement_1): 4556.

https://doi.org/10.1182/blood-2019-124211

Published: 2019

Journal Articles

Comparison of Chronic Graft-Versus-Host Disease Severity and Functional Status after Cord Blood, Haploidentical Related and 1-Allele Mismatched Unrelated Donor Hematopoietic Cell Transplantation

Giancarlo Fatobene, MD, Barry E. Storer, PhD, Rachel B. Salit, MD, Stephanie J. Lee, MD PhD, Paul J. Martin, MD, Guang-Shing Cheng, MD, Colleen Delaney, MD, Frederick R. Appelbaum, MD, Brenda M. Sandmaier, MD, Filippo Milano, MD PhD, Mary E. Flowers, MD

Blood (2017) 130 (Supplement 1): 73.

https://doi.org/10.1182/blood.V130.Suppl_1.73.73

Published: 2017

Journal Articles

Quality of Life of Informal Caregivers of Hematopoietic Cell Transplant Recipients

Kareem Jamani, MD, Lynn E. Onstad, ScM, Rachel B. Salit, MD, Mary E. Flowers, MD, Paul A. Carpenter, MD, Stephanie J. Lee, MD PhD

Blood (2017) 130 (Supplement 1): 280.

https://doi.org/10.1182/blood.V130.Suppl_1.280.280

Published: 2017

Journal Articles

Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

Blood (2015) 126 (23): 65.

https://doi.org/10.1182/blood.V126.23.65.65

Published: 2015

Journal Articles

Survival after T-Cell Replete Haploidentical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor (MUD) Transplant for Lymphoid Malignancies

Alberto Mussetti, MD, Abraham Sebastian Kanate, MD, Mohamed A Kharfan-Dabaja, MD, Kwang Woo Ahn, PhD, Alyssa DiGilio, MS, Stefan O Ciurea, MD, Philippe Armand, MD PhD, Rachel B. Salit, MD, Timothy S. Fenske, MD MS, Sonali M. Smith, MD, Anna Sureda, MD PhD, Javier Bolanos-Meade, MD, Mehdi Hamadani, MD

Blood (2015) 126 (23): 194.

https://doi.org/10.1182/blood.V126.23.194.194

Published: 2015

Journal Articles

Comorbidity Index in the Context of Cord Blood Transplantation: An Accurate Predictor of Treatment Related Mortality?

David C. Oliver, Filippo Milano, MD PhD, Colleen Delaney, MD MSC, Mohamed L. Sorror, MD MSc, Rachel B. Salit, MD

Blood (2014) 124 (21): 1205.

https://doi.org/10.1182/blood.V124.21.1205.1205

Published: 2014

Journal Articles

Second Allogeneic Transplant with Cord Blood for Treatment of Failed First Allogeneic Transplant Due to Primary Graft Failure or Disease Recurrence

Rachel B. Salit, MD, Filippo Milano, MD PhD, Ivy B. Riffkin, David C. Oliver, Nancy L. Anderson, Colleen Delaney, MD MSC

Blood (2014) 124 (21): 3940.

https://doi.org/10.1182/blood.V124.21.3940.3940

Published: 2014

Journal Articles

Infectious Complications After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation With Or Without Alemtuzumab Based In Vivo Lymphocyte Depletion

Brian C. Shaffer, MD, Andrew Flynn, David Moorshead, Zach Powell, Jennifer Hsu, RN, Rachel B Salit, MD, Frances T. Hakim, PhD, Ronald E. Gress, MD, Michael Bishop, MD, Juan Gea-Banacloche, MD, Steven Z. Pavletic, MD

Blood (2013) 122 (21): 4580.

https://doi.org/10.1182/blood.V122.21.4580.4580

Published: 2013

Journal Articles

Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen

Rachel B Salit, MD, Filippo Milano, MD, PhD, Jonathan A Gutman, MD, Michael B Maris, MD, Thomas Chauncey, MD, PhD, Finn Petersen, M.D., Colleen Delaney, MD, MSc

Blood (2013) 122 (21): 697.

https://doi.org/10.1182/blood.V122.21.697.697

Published: 2013

Journal Articles

Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.

Rachel B. Salit, MD, Frances T. Hakim, PhD, Michael R. Bishop, MD, Thea M. Friedman, PhD, Robert Korngold, PhD, Kira Goldgirsh, PhD, Sarfraz Memon, MD, Seth M. Steinberg, PhD, David Liewehr, MS, Daniel Peaceman, BS, Jennifer Wilder, RN, Kelly Bryant, RN, Daniel H. Fowler, MD, Juan Gea-Banacloche, MD, Ronald E. Gress, MD, Steven Z. Pavletic, MD

Blood (2012) 120 (21): 3054.

https://doi.org/10.1182/blood.V120.21.3054.3054

Published: 2012

Journal Articles

Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism

Rachel B. Salit, MD, Michael R. Bishop, MD, Steven Z. Pavletic, MD, Frances T. Hakim, PhD, Seth M. Steinberg, PhD, Jeanne Odom, RN, Kelly Bryant, RN, Jennifer Wilder, RN, Daniele N. Avila, CRNP, Bazetta Blacklock-Schuver, RN, Ronald E. Gress, MD, Daniel H. Fowler, MD

Blood (2011) 118 (21): 1937.

https://doi.org/10.1182/blood.V118.21.1937.1937

Published: 2011

Journal Articles

Assessing the Validity of the NIH Response Criteria for Chronic Graft-Versus-Host Disease (cGVHD): Consensus Measures Correlate with Clinical Outcomes,

Blood (2011) 118 (21): 4074.

https://doi.org/10.1182/blood.V118.21.4074.4074

Published: 2011

Journal Articles

Pilot Randomized Trial Comparing the Effects of Alemtuzumab and Cyclosporine Versus Tacrolimus, Methotrexate and Sirolimus on Graft Versus Host Disease Prevention, Engraftment and Immune Reconstitution After Reduced Intensity Unrelated Donor Transplantation.

Rachel B. Salit, MD, Steven Z. Pavletic, MD, Daniel H. Fowler, MD, Jennifer Wilder, RN, Kelly Bryant, RN, Seth M. Steinberg, PhD, Frances T. Hakim, PhD, Michael R. Bishop, MD

Blood (2010) 116 (21): 1245.

https://doi.org/10.1182/blood.V116.21.1245.1245

Published: 2010

Journal Articles

Use of Targeted Lymphocyte Depletion as a Personalized Approach to Improve Engraftment and Disease Control Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors

Rachel B. Salit, MD, Steven Z. Pavletic, MD, Daniel H. Fowler, MD, Jennifer Wilder, RN, Kelly Bryant, RN, Seth M. Steinberg, PhD, Frances T. Hakim, PhD, Michael R. Bishop, MD

Blood (2010) 116 (21): 3530.

https://doi.org/10.1182/blood.V116.21.3530.3530

Published: 2010

Journal Articles

Incidence, Risks, and Outcomes of Relapse Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma.

Michael R. Bishop, MD, Seth Steinberg, PhD, Nancy M. Hardy, MD, Steven Z. Pavletic, MD, Ronald E. Gress, MD, Rachel B. Salit, MD, Paula Layton, BSN, Daniel H. Fowler, MD

Blood (2010) 116 (21): 3451.

https://doi.org/10.1182/blood.V116.21.3451.3451

Published: 2010

Journal Articles

Allogeneic Hematopoetic Transplantation for CLL: Results of Combination Chemotherapy as Pre-Transplant Targeted Lymphocyte Depletion on Disease Response, Donor Chimerism, and Transplantation Outcomes.

Brian C Shaffer, MD, Marko Modric, David Liewehr, MS, Maryalice Stetler-Stevenson, MD, PhD, Diane C Arthur, MD, Seth Steinberg, PhD, Frances T Hakim, PhD, Kelly Bryant, Jeanne Odom, Paula Layton, BSN, Rachel B Salit, MD, Christoph Rader, PhD, Ronald E Gress, MD, Daniel H Fowler, MD, Michael R Bishop, MD, Steven Z Pavletic, MD

Blood (2010) 116 (21): 3476.

https://doi.org/10.1182/blood.V116.21.3476.3476

Published: 2010

Journal Articles

Targeted Lymphocyte Depletion: A Personalized Approach to Achieve Rapid Complete Donor Chimerism and Enhance Graft-Versus-Tumor Effects Following Reduced Intensity Allogeneic Stem Cell Transplantation for High-Risk Hematologic Malignancies.

Rachel B. Salit, MD, Seth Steinberg, PhD, Daniel H. Fowler, MD, Jeanne Odom, RN, Kelly Bryant, RN, Michael R. Bishop, MD

Blood (2009) 114 (22): 656.

https://doi.org/10.1182/blood.V114.22.656.656

Published: 2009

Journal Articles

Targeted Lymphocyte Depletion Prior to Reduced Intensity Allogeneic Stem Cell Transplantation: A Personalized Approach to Facilitate Engraftment.

Rachel B. Salit, MD, Seth Steinberg, PhD, Daniel H. Fowler, Jeanne Odom, RN, Kelly Bryant, RN, Michael R. Bishop, MD

Blood (2009) 114 (22): 865.

https://doi.org/10.1182/blood.V114.22.865.865

Published: 2009

NARROW

Post-Transplant Work Status of Young Adult Survivors of Allogeneic Hematopoietic Cell Transplant: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes

High Incidence of Herpes Zoster after Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis

Comparison of Chronic Graft-Versus-Host Disease Severity and Functional Status after Cord Blood, Haploidentical Related and 1-Allele Mismatched Unrelated Donor Hematopoietic Cell Transplantation

Quality of Life of Informal Caregivers of Hematopoietic Cell Transplant Recipients

Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

Survival after T-Cell Replete Haploidentical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor (MUD) Transplant for Lymphoid Malignancies

Comorbidity Index in the Context of Cord Blood Transplantation: An Accurate Predictor of Treatment Related Mortality?

Second Allogeneic Transplant with Cord Blood for Treatment of Failed First Allogeneic Transplant Due to Primary Graft Failure or Disease Recurrence

Infectious Complications After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation With Or Without Alemtuzumab Based In Vivo Lymphocyte Depletion

Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen

Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.

Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism

Assessing the Validity of the NIH Response Criteria for Chronic Graft-Versus-Host Disease (cGVHD): Consensus Measures Correlate with Clinical Outcomes,

Pilot Randomized Trial Comparing the Effects of Alemtuzumab and Cyclosporine Versus Tacrolimus, Methotrexate and Sirolimus on Graft Versus Host Disease Prevention, Engraftment and Immune Reconstitution After Reduced Intensity Unrelated Donor Transplantation.

Use of Targeted Lymphocyte Depletion as a Personalized Approach to Improve Engraftment and Disease Control Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors

Incidence, Risks, and Outcomes of Relapse Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma.

Allogeneic Hematopoetic Transplantation for CLL: Results of Combination Chemotherapy as Pre-Transplant Targeted Lymphocyte Depletion on Disease Response, Donor Chimerism, and Transplantation Outcomes.

Targeted Lymphocyte Depletion: A Personalized Approach to Achieve Rapid Complete Donor Chimerism and Enhance Graft-Versus-Tumor Effects Following Reduced Intensity Allogeneic Stem Cell Transplantation for High-Risk Hematologic Malignancies.

Targeted Lymphocyte Depletion Prior to Reduced Intensity Allogeneic Stem Cell Transplantation: A Personalized Approach to Facilitate Engraftment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only